Zacks Small Cap Reduces Earnings Estimates for Soligenix

Soligenix, Inc. (NASDAQ:SNGX) – Analysts at Zacks Small Cap reduced their FY2025 EPS estimates for Soligenix in a research note issued to investors on Wednesday, March 26th. Zacks Small Cap analyst D. Bautz now anticipates that the biopharmaceutical company will post earnings of ($3.09) per share for the year, down from their prior forecast of ($2.93). The consensus estimate for Soligenix’s current full-year earnings is ($4.65) per share. Zacks Small Cap also issued estimates for Soligenix’s FY2026 earnings at ($2.02) EPS.

Soligenix (NASDAQ:SNGX) last announced its quarterly earnings data on Friday, March 21st. The biopharmaceutical company reported ($1.14) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.95) by ($0.19). The firm had revenue of $0.20 million during the quarter, compared to analysts’ expectations of $0.20 million. Soligenix had a negative net margin of 1,473.38% and a negative return on equity of 223.29%. During the same quarter in the previous year, the business posted ($12.66) EPS.

Soligenix Trading Down 2.6 %

SNGX opened at $2.21 on Friday. Soligenix has a twelve month low of $1.83 and a twelve month high of $14.92. The firm has a market capitalization of $5.55 million, a PE ratio of -0.29 and a beta of 2.03. The firm’s 50-day moving average price is $2.34 and its 200 day moving average price is $3.07.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Soligenix stock. Geode Capital Management LLC boosted its stake in shares of Soligenix, Inc. (NASDAQ:SNGX) by 42.1% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 26,094 shares of the biopharmaceutical company’s stock after buying an additional 7,729 shares during the period. Geode Capital Management LLC owned 1.04% of Soligenix worth $71,000 at the end of the most recent quarter. Institutional investors and hedge funds own 3.60% of the company’s stock.

Soligenix Company Profile

Soligenix, Inc, a late-stage biopharmaceutical company, focuses on developing and commercializing products to treat rare diseases in the United States. The company operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a novel photodynamic therapy, which has completed Phase III clinical trial for the treatment of cutaneous T-cell lymphoma; SGX942, an innate defense regulator technology that is in Phase III clinical trial for the treatment of inflammatory diseases, including oral mucositis in head and neck cancer; SGX302, an IDR technology which is in Phase IIa study to treat mil-to-moderate Psoriasis; and SGX945 and IDR technology that is in Phase IIa protocol for the treatment of Aphthous Ulcers in Behçet's Disease.